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Revo-i assisted robotic central pancreatectomy
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Central pncreatectomy (CP) can be one of procedures for function-preserving pancreatectomy for patients with benign 
or low grade malignant pancreatic tumors. Surgeons have to deal with two cut surface of the pancreas when performing 
CP, which can be associated with severe complication, such as postoperative pancreatic fistula. Fine and delicate 
surgical skill is highly required for safe CP. With the advance of minimally invasive surgery, CP is now thought to 
be one of appropriate procedures for function-preserving minimally invasive pancreatectomy. Robotic surgery is thought 
to make complicated surgical procedure easy and effective. Recently, Korean robotic surgical system, Revo-i, was 
successfully developed by Meeraecompany and have been proved its safety and feasibility in several recent reports. 
A 56-year old woman was referred for a body of pancreatic lesion. Contrast abdominopelvic CT revealed a pancreatic 
body tumor measuring around 1.2 cm in diameter. The patient underwent a robot-assisted central pancreatectomy 
using Revo-i. The patient endured the procedure well and was discharged to home at postoperative day 9. This report 
showed a successful case of central pancreatectomy performed with the Korean robotic surgical system Revo-i. (Ann 
Hepatobiliary Pancreat Surg 2020;24:547-550)
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INTRODUCTION
Central pncreatectomy (CP) was rare surgical proce-
dure. Many pancreatic surgeons hesitated CP because they 
have to deal with two cut surface of the pancreas, which 
can be associated with severe complication, such as post-
operative pancreatic fistula (POPF).1,2 In fact, POPF after 
CP is reported to be high, up to 41%.2,3 However, with 
the advance of minimally invasive surgery, CP is now 
thought to be one of appropriate procedures for function- 
preserving minimally invasive pancreatectomy. Unlike usual 
pancreatic cancer, patients with pancreatic benign and low 
grade malignant neoplasms can be expected for long-term 
survival. Therefore, their quality of life should be also 
considered when planning treatment options for them. 
There are literatures reporting minimally invasive CP is 
safe and effective in preserving exocrine and endocrine 
pancreatic function.4-7
For CP, remnant pancreas should be managed following 
segmental resection of the pancreas. Most potential candi-
dates for CP are benign and low grade malignant neo-
plasm, which usually have soft remnant pancreas with very 
small pancreatic duct after limited resection of the pan-
creas. In addition, some anatomical circumstances are a 
little different from those in pancreticoduodenectomy (PD, 
Table 1). Comparing to remnant pancreas in PD, pancre-
atic duct size is much smaller, and splenic artery is em-
bedded into the pancreas, which is very difficult to take 
a secure suturing without vascular damage. Therefore, 
precise and advanced surgical techniques are essential in 
managing remnant pancreas when performing CP. Espe-
cially, laparoscopic pancreatico-jejunostomy, or pancreati-
co-gastrostomy is technically very difficult to perform due 
to fundamental disadvantages of laparoscopic surgery. 
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Fig. 1. External view of Revo-i robotic surgical system. (A) Front view of surgical console of Revo-i surgical system. (B) 
Lateral view of surgical console of Revo-i surgical system. (C) External view after completion of robotic docking to the patient’s
side ports.
Table 1. Considering points in dealing with remnant pancreas 





Pancreatic duct, size Small/large Smaller







splenic artery from 
remnant pancreas
Far Embedded
Cut surface area of 
remnant pancreas 
(division line location)
Small (neck) Larger (body)
Therefore, fine and delicate surgical skill is highly re-
quired for safe CP. 
Robotic surgical system has been introduced to over-
come limitation of laparoscopic surgery. Robotic surgery 
is thought to make complicated surgical procedure easy 
and effective. Recently, meeraecompany (Korea) success-
fully develop Korean robotic surgical system (Revo-i), 
which is very similar to the current da Vinci system (Fig. 
1).8,9 Several recent reports suggested safety and feasi-
bility of Revo-i in clinical application of minimally in-
vasive surgery.8-11
Last year, in 2018, we performed the first Revo-i pan-
creaticoduodenectomy, showing the potential feasibility and 
safety of Revo-i in far advanced minimally invasive 
surgery.12 The present case is another story to demonstrate 
clinical usability of Revo-i in far advanced minimally in-
vasive pancreatectomy. In this case, we report a success-
ful Revo-i assisted robotic CP for neuroendocrine tumor 
of the pancreas. The current status of Korean robotic sur-
gical system and future perspectives are also discussed.
CASE
The patient is a 56-year-old female who was screened 
by computed tomography (CT) scan of abdomen and pel-
vis for epigastric pain in September 2019 in a local clinic. 
She had no specific medical histories. On the CT scan, 
there was about 1.2 cm sized hyperenhancing lesion in the 
body of the pancreas (Fig. 2A). All the results of labo-
ratory tests were in normal range including amylase and 
lipase. Magnetic resonance imaging (MRI) also showed 1 
cm enhancing lesion in the body of the pancreas. There 
were no vascular encasements, ductal dilatation or distant 
metastatic lesions. No variations of anatomy around pan-
creas were found. 
She underwent Revo-i assisted robotic central pan-
createctomy on December 2nd, 2019. Firstly, we per-
formed laparoscopic resection of the tumor (Fig. 2B). 
After robotic docking to the port sites (Fig. 1C), Revo-i 
reconstruction including pancreatojejunostomy (PJ). The 
proximal portion of pancreas was dissected by endo-GIA 
stapler. Distal portion was dissected by endo-scissor and 
electrocautry device for bleeding control. PJ was stitched 
by prolene 4-0 interrupted and a short stent was inserted 
(Fig. 2C, D). Total operation time was 295 minutes. 
Estimated blood loss was 50 ml. 
The lesion proved to be a neuroendocrine tumor. Tumor 
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Fig. 2. Preoperative CT and 
operative view. (A) Preoperative 
CT scan. (B) Operation view 
after laparoscopic resection. (C) 
Revo-i PJ (duct-to-mucosa), note 
1 mm-silicone pancreatic stent 
(white arrow). (D) Completion 
of Revo-i PJ. Pp, proximal pan-
creas; Dp, distal remnant pan-
creas; SV, splenic vein; LGV, 
left gastric vein; SA, splenic 
artery; S, stomach; J, jejunum. 
size was about 1.0×0.9 cm and the mitotic count was 0/10 
HPF, defined as grade 1 according to 2017 WHO classi-
fication*. The lesion was confined to pancreas and all 
margins were negative from tumor.
The patient endured the procedure well and without 
complication. Drain was removed postoperative day 7. 
Postoperative biochemical POPF was noted. She tolerated 
more than half of soft meals without any specific symp-
toms. She was discharged to home at postoperative day 
9. There were no other surgical or medical complications. 
DISCUSSION
We have been working on testing clinical feasibility 
and safety of Revo-i in minimally invasive surgery. Last 
year, we successfully performed the first Revo-i assisted 
PD in patients with insulinoma.12 At that time, Revo-i was 
applied for pancreaticojejunostomy (duct-to-mucosa), mana-
ging remnant soft pancreas with less than 2 mm pancre-
atic duct and choledochojejunostomy after laparoscopic 
resection of the pancreaticoduodenal unit. In present case 
of CP, Revo-i was also used for pancreaticojejunostomy 
(duct-to-mucosa) following laparoscopic segmental resec-
tion of the pancreas. However, dealing remnant pancreas 
in CP can be much more difficult because there are some 
anatomical differences between PD and CP (Table 1). 
Especially, adjusting the location for duct-to-mucosa anas-
tomosis requires for advanced technical skills for safe lap-
aroscopic surgical procedure. Therefore, robotic surgical 
system with articulating wrist-like motion of the instru-
ment is very helpful for managing this surgical step. The 
present case successfully demonstrated that Revo-i can be 
applicable to PJ with different situations from that of PD 
during CP.
Based on surgeons’ feedback during previous pre-
clinical and clinical trial,8,10 meeraecompany tries to im-
prove the quality of Revo-i surgical system. As results, 
comparing with initial stage of Revo-i, overall surgical 
system became stable, and coupling capability between 
movement of surgeon in console and robotic instrument 
got improved. However, comparing the current da Vinci 
system, the detailed quality to mechanically transfer sur-
geon’s movement to robot-instrument’s motion seems def-
initely inferior, leaving some engineering issues to be 
solved in near further. In addition, vision quality also need 
to be improved and another energy devices needs to be 
developed.
It is thought that the current da Vinci surgical system 
is the first wave in era of far advanced minimally invasive 
surgery. Recently another new version of robotic surgical 
systems,13 including the present Revo-i, has been devel-
oped, introduced, and will be applied in real clinical 
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practice. Currently, cost-benefit issue of robotic surgical 
system is regarded as one of the great obstacles to over-
come14,15 for widely use of robotic surgical system. It is 
hoped that the current movement can provide more com-
fortable condition for clinical application of robotic surgi-
cal system for safe and effective minimally invasive sur-
gery in near future. The second wave of robotic surgery 
is coming.
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